$ARGX

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

argenx will report Q1 2026 financial results on May 7, 2026, offering investors insight into the immunology company's clinical progress and commercial trajectory.

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.

Folia Health and Argenx launch at-home real-world evidence study capturing CIDP patient symptom data over six months using app-based reporting platform.

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.

Biotech startup Unnatural Products secures $45M Series B funding led by The Venture Collective and inks $1.7B milestone deal with Novartis for oral peptide therapeutics.

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

Argenx's VYVGART achieves Phase 3 success for ocular myasthenia gravis, meeting primary endpoint. Company plans FDA application to expand indication for the rare eye disorder treatment.

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.